Pacylex Pharmaceuticals

Pacylex Pharmaceuticals PCLX-001 kills leukemia and lymphoma tumors in animals. Clinical studies in 2020.

Pacylex is a Canadian oncology company exploiting a new target in cancer biology with a first-in-class, oral drug to kill cancer cells while leaving normal cells unharmed.

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).
11/04/2025

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the W...
11/04/2025

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the World ADC Congress in San Diego. ADCs with zelenirstat were 20->1,000 fold more potent against prostate and breast cancer cell lines than zelenirstat alone including a breast cancer line resistant to most ADCs.
https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-and-heidelberg-pharma-present-zelenirstat-antibody-drug-conjugate-data-at-the-16th-annual-world-adc?_gl=1*1hxfm9e*_gcl_au*MzAwNzk1NDg0LjE3NTU0NTcyMzQuMTcyNDM5NjU5Ni4xNzYyMjI4MjYyLjE3NjIyMjgyNzQ.

Edmonton, Alberta, Canada and Heidelberg Pharma, Ladenburg, Germany, November 4, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Heidelberg Pharma AG (FSE: HPHA) is a clinical...

Once again we head to BIO to meet with partners and seek new investors and partners for our oral zelenirstat in promisin...
06/10/2025

Once again we head to BIO to meet with partners and seek new investors and partners for our oral zelenirstat in promising clinical trials in acute myeloid leukemia patients and our NMT inhibitor class of new ADC payloads.

Edmonton, Alberta, Canada June 10, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is a proprietary, potent, NMTi in clinical trials as a first-in-class treatment for he...

AACR poster on zelenirstat from the lab of our CSO, Dr. Luc Berthiaume, with his grad student Rony Pain presenting.
05/05/2025

AACR poster on zelenirstat from the lab of our CSO, Dr. Luc Berthiaume, with his grad student Rony Pain presenting.

05/05/2025

Headed to Boston to present our molecules as a new class of payloads for antibody drug conjugates (ADCs).

Pacylex is proud to announce that we have begun dosing acute myeloid leukemia patients with oral zelenirstat. This is th...
03/18/2025

Pacylex is proud to announce that we have begun dosing acute myeloid leukemia patients with oral zelenirstat. This is the indication we hope to bring to market first and for which we already have Orphan Drug and Fast Track designations.

Edmonton, Alberta, Canada March 17, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is under clinical investigation as a first-in-class targeted therapy for t...

February is a surprisingly busy time for investor conferences building on the momentum of JP Morgan Healthcare week in J...
02/03/2025

February is a surprisingly busy time for investor conferences building on the momentum of JP Morgan Healthcare week in January. Pacylex is involved in three in the next two weeks.

Edmonton, Alberta, Canada February 3, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) as targeted therapies for cancer. Oral zelenirstat is in development for the treatment of hematologic...

Wonderful article on Pacylex today from University of Albert in their Folio newsletter:
12/09/2024

Wonderful article on Pacylex today from University of Albert in their Folio newsletter:

University of Alberta spinoff Pacylex has spent 12 years pushing its first-in-class cancer treatment forward from a research lab idea to the stage of Phase 2 human trials with the potential to benefit people with both blood and solid tumours. It would not have happened without teamwork between scien...

We are very pleased to welcome Michael Kamdar, an experienced biotech executive and deal maker to the Pacylex Pharmaceut...
11/07/2024

We are very pleased to welcome Michael Kamdar, an experienced biotech executive and deal maker to the Pacylex Pharmaceuticals Board of Directors.

Edmonton, Alberta, Canada November 7, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is the only clinical-stage pharmaceutical company developing N-myristoyltransferase inhibitors (NMTis) as targeted therapies for the treatment of hematologic cancers. Pacylex also offers NMTis as payloads for antibody...

15th World ADC conference (https://lnkd.in/eGTS4HZX) offered us a great opportunity to continue to introduce our NMT inh...
11/06/2024

15th World ADC conference (https://lnkd.in/eGTS4HZX) offered us a great opportunity to continue to introduce our NMT inhibitor family a potential new ADC payloads. Pacylex has the only clinically validated NMT inhibitor, zelenirstat, with an acceptable safety profile and early signs of efficacy in Phase 1.

15th World ADC conference (https://lnkd.in/eGTS4HZX) offered us a great opportunity to continue to introduce our NMT inhibitor family a potential new ADC…

Excited to present the first in class NMT inhibitor Zelenirstat at BIO Investors Forum. It is the lead in a new class of...
10/15/2024

Excited to present the first in class NMT inhibitor Zelenirstat at BIO Investors Forum. It is the lead in a new class of ADC payload for solid tumors as well as an exciting potential therapy for leukemia and lymphoma.

Edmonton, Alberta, Canada October 14, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) as targeted therapies for the treatment of hematologic cancers and as payloads for antibody drug conj...

Address

4000, 10230 Jasper Avenue
Edmonton, AB
T5J4P6

Website

Alerts

Be the first to know and let us send you an email when Pacylex Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Pacylex Pharmaceuticals:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Building a NEW Cancer Therapy

Pacylex is a Canadian oncology company exploiting a new discovery in cancer biology which may explain how some cancers arise from normal cells. The company is developing a first in class, small molecule, oral chemotherapeutic, PCLX-001, to exploit this cancer mechanism by turning on selective lethality, apoptosis, in these cancer cells. Animal tests show this drug candidate completely eliminates tumors in 4 different animal models of blood cancers (leukemias and lymphomas). PCLX-001 also kills many solid tumor cancer cell lines and retards tumor growth in some animal models of lung and breast cancer.

Long-term survival of patients with lymphoma and especially leukemia is poor. The lymphoma market is ~$5B with few new therapies. The leukemia market is transitioning from generic chemotherapy to new branded therapies and is expected to grow dramatically in the next decade to >$1.9B. Oncology is the area of greatest pharmaceutical company interest and this summer, Pacylex was accepted into the first class of 4 companies in the new Merck-sponsored Accelerator in Edmonton, and is pursuing the investment and experiments necessary to begin investigations in patients.